[Federal Register Volume 59, Number 168 (Wednesday, August 31, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-21520]


[[Page Unknown]]

[Federal Register: August 31, 1994]


-----------------------------------------------------------------------


DEPARTMENT OF HEALTH AND HUMAN SERVICES
 

Prospective Grant of Exclusive License: Methods of Producing 
Viral Proof Barriers

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), 
Department of Health and Human Services, is contemplating the grant of 
a worldwide, limited field of use, exclusive license to practice the 
invention embodied in U.S. Patent Application Number 07/906,716, 
entitled ``Method for Viral-Proofing a Protective Barrier,'' to White 
Knight Health Care Inc., having a place of business in Ashville, North 
Carolina. The patent rights in these inventions have been assigned to 
the United States of America. Foreign patent applications are pending 
for the subject U.S. Patent Application.
    The prospective license will be royalty-bearing and will comply 
with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The 
field of use for the proposed license will be health care worker 
protective clothing such as gowns, surgical masks, and surgical drapes. 
The prospective exclusive license may be granted unless, within sixty 
(60) days from the date of this published notice, NIH receives written 
evidence and argument that establishes that the grant of the exclusive 
license would not be consistent with the requirements of 35 U.S.C. 209 
and 37 CFR 404.7.
    This invention relates to methods of producing viral proof barriers 
such as surgical gowns, drapes, and the like. Tests have confirmed that 
barriers treated with the methods of the subject invention can repel 
virus particles such as herpes simplex virus (HSV), hepatitis B, and 
other viral particles.

ADDRESSES: Requests for a copy of the subject patent application, 
inquiries, and comments relating to the contemplated license should be 
directed to: J. E. Fahner-Vihtelic, Office of Technology Transfer, 
National Institutes of Health, 6011 Executive Boulevard, Suite 325, 
Rockville, Maryland 20852-3804. A signed confidentiality agreement will 
be required to receive copies of patent applications. Properly filed 
competing applications for a license filed in response to this notice 
will be treated as objections to the grant of the contemplated license. 
Only written comments and/or applications for a license which are 
received by the NIH Office of Technology Transfer on or before October 
31, 1994 will be considered.

    Dated: August 20, 1994.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 94-21520 Filed 8-30-94; 8:45 am]
BILLING CODE 4140-01-P